Anti-Human TRAIL (Drozitumab Biosimilar)
Catalog #500020
| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 500020 | 1 mg | $250.00 | ||
| 500020 | 5 mg | $750.00 | ||
| 500020 | 20 mg | $2,000.00 |
Product Details
Drozitumab biosimilar is a fully human monoclonal antibody that specifically targets Death Receptor 5 (DR5, also known as TRAIL-R2), a key receptor involved in apoptosis induction in cancer cells. As a biosimilar to the reference biologic Drozitumab, this antibody is designed for oncology research, apoptosis studies, and targeted cancer therapy development.
Specifications
| Clone | Drozitumab |
|---|---|
| Reactivities | Human |
| Isotype | Human IgG1 |
| Recommended Isotype Control | Human IgG1 isotype control |
| Format | Liquid |
| Formluation | PBS, pH 6.0 |
| Sterility | 0.2 µm filtered |
| Clonality | Recombinant |
| Conjugation | Unconjugated |
| Immunogen | Human TRAIL |
| Host | CHO cells |
| Purity | >95% (HPLC, SDS-PAGE) |
| Endotoxin | < 1.0 EU/mg (LAL assay) |
| Grade | In vivo ready (RUO) |
| Application | Neutralization; Flow Cytometry; ELISA; WB |
| Purification | Protein A |
| Storage Conditions | 2-8 °C, Avoid freeze / thaw cycle |
| Shelf Life | 6 months |
| Regulatory Status | RUO |